Shares of Danish biotechnology firm Genmab rose 12% in European trading on Monday following the announcement of positive results from a late-stage clinical trial of its experimental ovarian cancer drug, rinatabrat sesutecan (Rina-S). The company disclosed on Friday that the drug significantly reduced both the risk of death and disease progression in patients with advanced ovarian cancer when compared with standard chemotherapy.

According to Genmab, Rina-S decreased the risk of death by 57% and lowered disease progression risk by 71%, meeting the primary and key secondary endpoints of the trial. These results mark the first late-stage data for the drug, bolstering the company’s confidence in its future therapeutic potential. Jan van de Winkel, Genmab’s CEO, highlighted the unprecedented efficacy demonstrated by Rina-S in this patient population.

Analysts from JPMorgan noted that the strong performance of Rina-S, combined with recent success from Genmab’s lymphoma drug Epkinly and anticipated positive late-stage trial results for postemteman, an investigational treatment for head and neck cancer, could enhance investor sentiment toward the company. The broad pipeline’s progress suggests potential for sustained growth in the competitive oncology market.

In addition to the ovarian cancer data, Genmab released weekend follow-up findings from a mid-stage study of petostamab for colorectal cancer. The company described the results as showing a promising depth and durability of response, further underscoring the expanding potential of its drug candidate portfolio.

Genmab’s latest clinical outcomes arrive amid a broader effort within the industry to develop more effective treatments for difficult-to-treat cancers, reflecting ongoing advances in targeted therapies and immuno-oncology. The company’s continued research and development activities position it as a potentially significant player in oncology therapeutics.